Synageva BioPharma Corp Receives Fair Value Rating from Janney Montgomery Scott (GEVA)
Synageva BioPharma Corp (NASDAQ:GEVA)‘s stock had its “fair value” rating reiterated by investment analysts at Janney Montgomery Scott in a note issued to investors on Tuesday. They currently have a $111.00 price target on the stock, up from their previous price target of $107.00. Janney Montgomery Scott’s price objective suggests a potential upside of 22.72% from the company’s current price.
Shares of Synageva BioPharma Corp (NASDAQ:GEVA) traded down 13.69% on Tuesday, hitting $90.45. 1,055,634 shares of the company’s stock traded hands. Synageva BioPharma Corp has a 52 week low of $42.90 and a 52 week high of $119.42. The stock’s 50-day moving average is $87.33 and its 200-day moving average is $86.86. The company’s market cap is $2.986 billion.
Synageva BioPharma Corp (NASDAQ:GEVA) last issued its quarterly earnings data on Friday, May 2nd. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $0.03. Analysts expect that Synageva BioPharma Corp will post $-5.93 EPS for the current fiscal year.
In other Synageva BioPharma Corp news, Director Barry D. Quart sold 1,375 shares of Synageva BioPharma Corp stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $100.00, for a total value of $137,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of other firms have also recently commented on GEVA. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Synageva BioPharma Corp in a research note on Tuesday. They now have a $110.00 price target on the stock, down previously from $115.00. Separately, analysts at Citigroup Inc. initiated coverage on shares of Synageva BioPharma Corp in a research note on Tuesday. They set a “neutral” rating and a $113.00 price target on the stock. Finally, analysts at Leerink Swann reiterated a “market perform” rating on shares of Synageva BioPharma Corp in a research note on Thursday, May 15th. They now have a $89.00 price target on the stock, down previously from $101.00. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Synageva BioPharma Corp presently has an average rating of “Buy” and an average price target of $109.11.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.